Two-year efficacy of adefovir dipivoxil for the treatment of chronic hepatitis B,compensated or decompensated cirrhosis

Objective To investigate 2-year antiviral efficacy of adefovir dipivoxil(ADV) on the patients with chronic hepatitis B,compensated or decompensated cirrhosis.Methods The treatment-nave patients with chronic hepatitis B(32 cases,CHB group),compensated cirrhosis(10 cases,compensated cirrhosis group) and decompensated cirrhosis(14 cases,decompensated cirrhosis group) were treated with ADV for 2 years.Biochemical markers such as ALT and virological markers such as HBV DNA were detected at baseline and at every 3-month interval.Results The baseline characteristics of the 3 groups were comparable with no significant difference.ALT normalization rate and HBeAg seroconversion rate of the 3 groups were not significantly different after 1year and 2-year ADV treatment(P 0.05).After 2-year ADV treatment,median reduction of HBV DNA levels was 5.9 log10 U/ml in CHB group,6.2 log10 U/ml in compensated cirrhosis group,and 2.9 log10 U/ml in decompensated cirrhosis group.Virologic response in decompensated cirrhosis group was worse than that in CHB group or compensated cirrhosis group after 6-month ADV treatment.Conclusion After 2 years of ADV treatment,virologic response in the patients with decompensated cirrhosis is worse than that in the patients with CHB or compensated cirrhosis.